Compare Tidewater Inc (TDW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs 10X Genomics Inc — how do they compare? Tidewater Inc trades at $92.71 (market cap $4.54B), while 10X Genomics Inc trades at $57.59 (market cap $7.61B). The key difference: 10X Genomics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| TDW | TXG | |
|---|---|---|
Market Cap | $4.54B | $7.61B |
Sector | Utilities | Health |
52-Week High | $91.20 | $58.57 |
52-Week Low | $47.29 | $11.34 |
Enterprise Value | $4.58B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $90.20, up 0.64% today, with a bullish technical signal driven by moving averages and ADX. Recent Q2 2026 earnings beat estimates (EPS $0.43 vs. $0.32 expected, Zacks Investment Research, 2026-08-03), though quarterly EPS has missed expectations in three of the last four quarters. The company maintains strong profitability with an 18.34% net margin and robust cash flow from operations of $379.11 million in 2025.
Outlook is mixed: bullish technicals and institutional interest support upside, but earnings misses and a high RSI near overbought levels pose risks. Analyst consensus leans hold (57.7%), with valuation metrics like P/E of 18.5 suggesting fair pricing. Key risks include operational costs from Middle East conflicts and revenue volatility.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
